[Helsinki Declaration--next version].

Area of Science:

• Bioethics
• Medical Research Ethics
• Human Subject Protection

Background:

• The revised Helsinki Declaration introduces enhanced protections for research participants, including provisions for compensation and vulnerable groups.
• It also refines guidelines on post-study arrangements and placebo use in clinical research.

Discussion:

• The updated Declaration inadequately addresses the ethical considerations surrounding the use of human biological materials and data.
• While requiring informed consent for identifiable data, it omits mandatory Research Ethics Committee review for all studies involving human biological materials, regardless of identifiability.
• The lack of a clear definition for "anonymisation" in the Declaration permits variable, potentially unethical, local interpretations.

Key Insights:

• The Declaration's updates offer improved participant welfare but fall short in protecting donors of biological materials.
• Mandatory ethical review by Research Ethics Committees for all research using human biological materials is not explicitly enforced.
• Ambiguity in the term "anonymisation" poses risks to ethical standards in data and material usage.

Outlook:

• Future revisions should prioritize comprehensive ethical frameworks for human biological material and data governance.
• Strengthening the role and mandate of Research Ethics Committees in overseeing research involving human biological materials is essential.
• Establishing clear, universally accepted definitions and ethical standards for anonymisation procedures is critical for donor protection.